Table 2. Prognostic factors for OS and PFS as shown by univariate and multivariate analyses.
| OS | PFS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| Variable | 5-year (%) | P value | HR (95% CI) | P value | 5-year (%) | P value | HR (95% CI) | P value |
| Sex | ||||||||
| Male | 54 | 0.70 | 41 | 0.80 | ||||
| Female | 47 | 42 | ||||||
| Location | ||||||||
| Pineal gland | 55 | 0.80 | 49 | 0.80 | ||||
| Others | 46 | 36 | ||||||
| Age | ||||||||
| < 3yr | 14 | 0.01 | 0.35 (0.13–0.95) | 0.04 | 14 | 0.03 | 0.48 (0.18–1.25) | 0.13 |
| ≥ 3yr | 56 | 0.09 (0.01–0.60)* | 0.01* | 40 | ||||
| KPS | ||||||||
| < 80 | 37 | 0.09 | 32 | 0.06 | 2.81 (1.04–7.62)* | 0.04* | ||
| ≥ 80 | 59 | 47 | ||||||
| Multiplicity | ||||||||
| Yes | 66 | 0.90 | 33 | 0.70 | ||||
| No | 49 | 41 | ||||||
| Metastasis | ||||||||
| Yes | 52 | 0.60 | 42 | 0.80 | ||||
| No | 48 | 41 | ||||||
| STR | ||||||||
| Yes | 61 | 0.01 | 0.58 (0.23–1.46) | 0.24 | 52 | 0.01 | 0.78 (0.32–1.90) | 0.58 |
| No | 22 | 0.13 (0.04–0.43)* | 0.00* | 14 | ||||
| RT | ||||||||
| Yes | 65 | <0.001 | 0.21 (0.08–0.52) | 0.00 | 56 | < 0.001 | 0.14 (0.06–0.37) | < 0.001 |
| No | 10 | 0 | 0.11 (0.04–0.37)* | < 0.001* | ||||
| CTx | ||||||||
| Yes | 50 | 0.60 | 43 | 0.20 | ||||
| No | 49 | 35 | ||||||
| Rad 51 | ||||||||
| Positive | 15 | 0.05* | 0 | 0.02* | 5.73 (1.65–19.89)* | 0.00* | ||
| Negative | 63 | 56 | ||||||
| LIN28, OLIG2 group | Group 1+2 vs. 3 | Group 1+2 vs. 3 | ||||||
| Primitive neural (group 1) | 0 | 0.08* | 0.19 (0.06–0.65)* | 0.01* | 0 | 0.01* | 0.17 (0.05–0.52)* | 0.00* |
| Oligoneural (group 2) | 43 | 29 | ||||||
| Mesenchymial (group 3) | 49 | 41 | ||||||
Abbreviations: OS, overall survival; PFS, progression-free survival; KPS, Karnofsky performance status; STR, subtotal resection; RT, radiotherapy; CTx, chemotherapy; HR, hazard ratio; CI, confidence interval
*: Results from subgroup analysis including 29 patients with available tumor biopsies.